SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 03/28/2025 at 07:00, 1 year 1 month ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD

Japan COPD Dupixent Phase 3 Results Biologic Medicine
PRESS RELEASE

published on 03/24/2025 at 19:27, 1 year 1 month ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/24/2025 at 07:35, 1 year 1 month ago

Sanofi launches the “Q1 2025 Aide mémoire” document

Financial Results Investors Sanofi Q1 2025 Memory Aid
PRESS RELEASE

published on 03/24/2025 at 07:30, 1 year 1 month ago

Press Release: Availability of the Q1 2025 Aide mémoire
Sanofi announced the availability of the Q1 2025 Aide mémoire on its website to assist in financial modeling, including non-comparable items and first quarter reminders

Sanofi Financial Modeling Aide Mémoire Q1 2025 Exclusivity Losses
PRESS RELEASE

published on 03/10/2025 at 21:09, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/08/2025 at 19:05, 1 year 2 months ago

Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
PRESS RELEASE

published on 03/08/2025 at 19:00, 1 year 2 months ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU

Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF

published on 02/25/2025 at 07:05, 1 year 2 months ago

Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment

Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 2 months ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results

Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE

published on 02/24/2025 at 21:27, 1 year 2 months ago

Sanofi: Disclosure of trading in own shares

Accesswire

Published on 05/23/2026 at 19:45, 8 hours 32 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 1 hour ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 1 hour ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 1 hour ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 1 hour ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 11 hours 47 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 12 hours 20 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 6 hours ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 8 hours ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 1 day 9 hours ago

Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring

Les Echos

Published on 05/22/2026 at 18:05, 1 day 10 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 15 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 1 day 19 hours ago

Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:50, 2 days 10 hours ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 2 days 10 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE